Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ethionamide sulfoxide
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Ethionamide sulfoxide is the major active metabolite of ethionamide, a second-line antitubercular agent. It is formed via hepatic metabolism and possesses antibacterial activity against Mycobacterium tuberculosis. Ethionamide sulfoxide contributes to the bacteriostatic and potentially bactericidal effects of ethionamide by inhibiting mycolic acid synthesis, thereby interfering with cell wall formation in mycobacteria. The metabolite is notable for retaining the antimicrobial properties of the parent drug and is integral to ethionamide’s pharmacologic profile[1][2][5].
- Other names
- 2-ethyl-4-pyridine sulfoxide
02
Targets
InhAMmpL3 (Mycobacterial membrane protein Large 3)
Beyond the preview
Go deeper on ethionamide sulfoxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ethionamide sulfoxide.